Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-05-15
2007-05-15
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S006120, C435S091100, C435S091310, C435S455000, C536S023100, C536S024500
Reexamination Certificate
active
10719370
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of HIF1α and/or HIF2α. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1α and HIF2α. Methods of using these compounds for modulation of HIF1α and/or HIF2α expression and for diagnosis and treatment of disease associated with expression of HIF1α and/or HIF2α are provided.
REFERENCES:
patent: 5695963 (1997-12-01), McKnight et al.
patent: 5882914 (1999-03-01), Semenza
patent: 6133246 (2000-10-01), McKay et al.
patent: 6395548 (2002-05-01), Lee et al.
patent: 6432927 (2002-08-01), Gregory et al.
patent: 6958240 (2005-10-01), Baird et al.
patent: 2003/0045686 (2003-03-01), Kaelin, Jr. et al.
patent: 2004/0086498 (2004-05-01), Krissansen et al.
patent: 2004/0152655 (2004-08-01), Yoon et al.
patent: 2004/0180357 (2004-09-01), Reich et al.
patent: 2005/0070474 (2005-03-01), Krissansen et al.
patent: 2005/0148496 (2005-07-01), Defranoux et al.
patent: 2005/0163781 (2005-07-01), Koninckx et al.
patent: 0147819 (1985-07-01), None
patent: WO 99/48916 (1999-09-01), None
patent: WO 00/09657 (2000-02-01), None
patent: WO 01/62965 (2001-08-01), None
patent: WO 02/34291 (2002-05-01), None
patent: WO 02/068466 (2002-09-01), None
patent: WO 02/086497 (2002-10-01), None
patent: WO 02/094862 (2002-11-01), None
patent: WO 03/040366 (2003-05-01), None
patent: WO 03/085110 (2003-10-01), None
patent: WO 2005/035759 (2005-04-01), None
Chirila, T.V. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Crooke, S.T., Antisense Research & Application, Chapter 1, pp. 1-50, Ed. by S.T. Crooke, Publi. by Springer-Verlag (1998).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Peracchi, A., Rev. Med. virol., vol. 14, pp. 47-64 (2004).
Branch, A.D., Trends in Biochem. Sci., vol. 23, pates 45-50 (1998).
Opalinska, J.B. et al., Nature Rev., vol. 1, pp. 503-514 (2002).
Andrew, A.S. et al., “Nickel requires hypoxia-inducible factor-1α, not redox signaling, to induce plasminogen activator inhibitor-1”Am. J. Physiol. Lung Cell Mol. Physiol., 2001, 281, L607-L615.
Caniggia, I. et al., “Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ3,”J. Clin. Investigation, 2000, 105(5), 577-587.
Caniggia, I. et al., “Oxygen and Placental Development During the First Trimester: Implications for the Pathophysiology of Pre-eclampsia,”Placenta, 2000, 21 Suppl. A, 14, S25-S30.
Drutel, G. et al., “Two splice variants of the hypoxia-inducible factor HIF-1α as potential dimerization partners of ARNT2 in neurons,”European N. Neurosc., 2000, 12, 3701-3708.
Furuta, G.T. et al., “Hypoxia-inducible Factor 1-dependent Induction of Intestinal Trefoil Factor Protects Barrier Function during Hypoxia,”J. Exp. Med., 2001, 193(9), 1027-1034.
Huang, L.E., et al., “Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway,”Proc. Natl. Acad. Sci. USA, 1998, 95, 7987-7992.
Iyer, N.V. et al., “Cellular and developmental control of O2homeostasis by hypoxia-inducible factor 1α,”Genes&Development, 1998, 12, 149-162.
Kakinuma, Y. et al., “Novel Molecular Mechanism of Increased Myocardial Endothelin-1 Expression in the Failing Heart Involving the Transcriptional Factor Hypoxia-Inducible Factor-1α Induced for Impaired Myocardial Energy Metabolism,”Circulation, 2001, 103, 2387-2394.
Maxwell et al., “Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation,”Exp. Nephrol., 2001, 9, 235-240.
Minchenko, A. et al., “Hypoxia-inducible factor-1 (HIF-1) mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKBF3) gene: its possible role in the Warburg effect,”J. Biol. Chem., 2001, 14, 21 pages.
Narravula, S. et al., “Hypoxia-Inducible Factor 1-Mediated Inhibition of Peroxisome Proliferator-Activated Receptor α Expression During Hypoxia,”J. Immunol., 2001, 166, 7543-7548.
Ravi, R. et al., “Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α,”Genes&Development, 2000, 14, 43-44.
Ryan, H.E. et al., “HIF-1α is required for solid tumor formation and embryonic vascularization,”EMBO J., 1998, 17(11), 3005-3015.
Semenza, G.L., “HIF-1 and human disease: one highly involved factor,”Genes&Development, 2000, 14, 1983-1991.
Semenza, G.L., “Hypoxia-Inducible Factor 1: Control of Oxygen Homeostasis in Health and Disease,”Pediatr. Res., 2001, 49(5), 614-617.
Sun, X. et al., “Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy,”Gene Therapy, 2001, 8, 638-645.
Sutter, C.H. et al., “Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations,”Proc. Natl. Acad. Sci. USA, 2000, 97(9), 4748-4753.
Thrash-Bingham, C.A. et al., “aHIF: a Natural Antisense Transcript Overexpressed in Human Renal Cancer and During Hypoxia,”J. Natl. Cancer Inst., 1999, 91(2), 143-151.
Wang, G.L. et al., “Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2tension,”Proc. Natl. Acad. Sci. USA, 1995, 92, 5510-5514.
Wang, G.L. et al., “Purification and Characterization of Hypoxia-inducible Factor 1,”J. Biol. Chem., 1995, 270(3), 1230-1237.
Yu, A.Y. et al., “Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α,”J. Clin. Investigation, 1999, 103(5), 691-696.
Zagzag, D. et al., “Expression of Hypoxia-Inducible Factor 1α in Brain Tumors,”Cancer, 2000, 88(11), 2606-2618.
Cockman, M.E. et al., “Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein,”J. Biol. Chem., 2000, 275(33), 25733-25741.
Conrad, P.W. et al., “The molecular basis of O2-sensing and hypoxia tolerance in pheochromocytoma cells,”Comparative Biochem. Physiol., 2001, Part B, 128, 187-204.
Conrad, W.P. et al., “EPAS1trans-Activation during Hypoxia Requires p42/p44 MAPK,”J. Biol. Chem., 1999, 274(47), 33709-33713.
Ema, M. et al., “A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates theVEGFexpression and is potentially involved in lung and vascular development,”Proc. Natl. Acad. Sci. USA, 1997, 94, 4273-4278.
Favier, J. et al., “Angiogenesis and Vascular Architecture in Pheochromocytomas,”Am. J. Pathology, 2002, 161(4), 1235-1246.
Flamme, I. et al., “Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2α,”Am. J. Pathology, 1998, 153(1), 25-29.
Flamme, I. et al., “HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels,”Mechan. Develop., 1997, 63, 51-60.
Giatromanolaki, A. et al., “Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival,”British J. Cancer, 2001, 85(6), 881-890.
Giatromanolaki, A. et al., “Hypoxia inducible factor 1α and 2α overexpression in inflammatory bowel disease,”J. Clin. Pathol., 2003, 56, 209-213.
Harris, A.L., “Hypoxia—A Key Regulatory Factor in Tumour Growth,”Nature Reviews, 2002, 2, 38-47.
Hirsila, M. et al., “Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia
Dobie Kenneth W.
Freier Susan M.
Marcusson Eric G.
Ward Donna T.
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals Inc. Patent Department
Knobbe Martens Olson and Bear LLP
Zara Jane
LandOfFree
Modulation of HIF1α and HIF2α expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of HIF1α and HIF2α expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of HIF1α and HIF2α expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3780115